+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 583 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are evaluating the cosmetic outcomes and quality of life for breast cancer patients undergoing breast reconstruction using 3D-printed biodegradable material breast implants. This study compares these results with traditional breast-conserving surgery and traditional silicone prosthesis breast reconstruction. It also explores the safety and potential medical issues related to using 3D-printed biodegradable implants for breast reconstruction in patients not suitable for breast-conserving surgery. Participants are divided into three groups one group receives breast reconstruction using 3D-printed biodegradable implants, the second undergoes traditional breast-conserving surgery, and the third has traditional silicone prosthesis breast reconstruction. The trial includes preoperative assessments, imaging with MRI, surgical planning with 3D printing of implants for the experimental group, and surgery according to each groups procedures. Postoperative care includes wound management, systemic therapies such as chemotherapy or endocrine therapy, and radiotherapy based on clinical guidelines. During the study, participants undergo regular follow-up with breast ultrasounds weekly for the first month and monthly thereafter, MRI scans at 3, 6, 12, and 24 months, and patient-reported outcome assessments using the BREAST-Q V2.0 scale to evaluate breast aesthetics, satisfaction, and quality of life. Telephone follow-ups occur monthly, with in-person visits every three months. The primary outcome measured is cosmetic effects and quality of life one year after surgery, alongside safety and long-term survival outcomes up to ten years.

Age: 18Years - 70YearsFEMALEPhase 2
1 location
S

Actively Recruiting

Researchers are evaluating the diagnostic effectiveness of 68Ga-PSMA PET scans compared to enhanced CT scans in detecting metastatic lesions in patients with locally advanced and advanced renal cell carcinoma. The study also aims to see if 68Ga-PSMA PET can influence treatment decisions for these patients. This prospective, multicenter trial is sponsored by Xijing Hospital and focuses on improving diagnosis and management for renal cancer with metastases. Participants in the study will receive both a 68Ga-PSMA PET scan and an enhanced CT scan simultaneously to compare their abilities to detect cancer spread. This diagnostic approach helps assess the additional value that 68Ga-PSMA PET may provide over standard CT imaging. The study does not involve any masking or placebo groups and includes only patients who meet specific clinical and imaging criteria. During the study, patients will undergo imaging within six weeks after diagnosis, and researchers will track how the 68Ga-PSMA PET results affect treatment choices. The primary measurement is the additional diagnostic value of the PSMA PET compared to CT over two years. Secondary outcomes include how often the PET scan changes treatment decisions. The study monitors patient safety and adherence, with a planned follow-up period to evaluate outcomes until December 2027.

Age: 18Years - 90YearsAll GendersPhase Not Applicable
9 locations
U

Actively Recruiting

Researchers are evaluating the use of a radioactive molecular probe called 99mTc-P137 combined with SPECTCT imaging to improve the diagnosis of prostate cancer. The study aims to enhance early detection, accurate tumor staging, treatment decisions, and prognosis assessment for patients suspected of having prostate cancer. This prospective study compares imaging results to surgical and pathological findings to establish clinical value. Participants will receive an injection of the 99mTc-P137 tracer followed by SPECTCT scans performed 2 hours after injection. Additional imaging findings will be collected up to 7 days after injection to optimize the imaging and diagnostic process. This study focuses on patients planning surgical resection or biopsy, using the probe to detect prostate cancer lesions accurately. During the study, participants will undergo multiple imaging assessments and provide clinical laboratory results including blood tests and PSA levels. Researchers will monitor the diagnostic accuracy of 99mTc-P137 SPECTCT imaging against pathological results. Participants must be able to complete the procedures independently, and their imaging and clinical data will be used to evaluate the probes value in prostate cancer diagnosis and prognosis.

Age: 18Years +MALEPhase Not Applicable
1 location
P

Actively Recruiting

Researchers are evaluating TQB2934, a special antibody designed to target multiple myeloma, a cancer affecting plasma cells. This antibody binds to T cells and cancer cells to activate the immune system to attack the disease. The study is a Phase 1 clinical trial focusing on safety and the bodys handling of the drug in patients with malignant plasma cell tumors. The study involves giving TQB2934 as a subcutaneous injection at doses of 40mg or 60mg. Treatment cycles occur once weekly during the first three cycles, then every two weeks for cycles four to six. If patients achieve a partial remission or better after six cycles, dosing continues every four weeks. Each treatment cycle lasts 28 days. Participants will undergo various assessments including blood tests to measure drug levels and immune response over 120 hours after each dose. Researchers will monitor adverse events for up to 24 months and evaluate treatment responses such as remission rates and survival outcomes. The total study participation includes treatment and long-term safety follow-up lasting up to two years.

Age: 18Years - 75YearsAll GendersPhase 1
14 locations
C

Actively Recruiting

Researchers are conducting a multicenter randomized controlled trial involving 120 patients with HER-2-positive gastric cancer at stages IB to II following surgery. The study aims to compare the effectiveness of combining anti-HER2 therapy with chemotherapy versus chemotherapy alone as adjuvant treatment after tumor resection. This Phase 2 trial is led by Xijing Hospital and involves 11 medical centers working together in China. Participants are randomly assigned to one of two groups. The control group receives chemotherapy appropriate to their cancer stage stage IB patients take oral tegafur twice daily for 14 days in six 21-day cycles, while stage II patients receive either the SOX or XELOX chemotherapy regimens, both including intravenous oxaliplatin on Day 1 plus oral drugs for 14 days per cycle, over six cycles. The experimental group receives the same chemotherapy regimens plus intravenous trastuzumab, starting with a loading dose followed by maintenance doses, administered concurrently with chemotherapy during six 21-day cycles. During the study, participants will be monitored for disease-free survival over five years after randomization, which is the primary outcome. Overall survival will also be tracked for up to five years. Assessments include safety and organ function evaluations before and during treatment. Participants will be involved in regular visits aligned with their chemotherapy cycles and followed long-term to measure treatment outcomes and monitor health status throughout the study duration.

Age: 18Years +All GendersPhase 2
1 location
P

Actively Recruiting

Researchers are evaluating the effectiveness and safety of B001 injection in patients who have neuromyelitis optica spectrum disorder NMOSD and test positive for aquaporin-4 antibodies. This condition involves recurrent attacks affecting the nervous system. The study is a multicenter, randomized, double-blind, placebo-controlled trial conducted in phases II and III to understand how well B001 works and how safe it is for these patients. Participants will receive intravenous doses of either B001 or a placebo on Day 1 and Day 15 during the randomized controlled period. The study includes two groups one receiving B001 injections and the other receiving placebo injections matching B001s schedule. The trial will extend over several years, monitoring patients closely for disease relapse and treatment side effects. During the study, participants will be regularly assessed for the time to their first NMOSD attack, changes in disability status, vision acuity, and opticospinal function. Researchers will also observe the annual relapse rate and document any adverse events. The trial includes safety monitoring for about three years to ensure comprehensive data collection on treatment impact and participant health.

Age: 18Years +All GendersPhase 2Phase 3
51 locations
E

Actively Recruiting

Researchers are evaluating the efficacy and safety of B007 in adults with generalized myasthenia gravis, a condition characterized by muscle weakness. This randomized, double-blind, placebo-controlled trial is sponsored by Shanghai Jiaolian Drug Research and Development Co., Ltd and aims to better understand how B007 may impact the daily activities affected by this condition. Participants will receive either B007 or a matching placebo through subcutaneous injections on days 1 and 15. The study includes different dose levels of B007 and compares outcomes over approximately 16 weeks for the primary measure, with additional assessments extending to about 24 weeks and safety monitoring for up to one year. Throughout the trial, participants will be monitored for changes in their myasthenia gravis symptoms using specific scales such as MG-ADL, QMG, MGQoL15r, and MGC. Researchers will also track any treatment-emergent adverse events. Participants are expected to maintain stable doses of their standard care treatments during the study, and the trial will last until the end of 2026, including follow-up periods for comprehensive safety and efficacy assessments.

Age: 18Years - 70YearsAll GendersPhase 2Phase 3
18 locations
A

Actively Recruiting

Researchers are evaluating the safety and effectiveness of a drug called B007 compared to cyclosporine in treating adults with primary membranous nephropathy, a kidney condition. This study is a multicenter, randomized, controlled, open-label trial conducted in phases II and III to better understand treatment options for this disease. Participants will be randomly assigned to receive either B007 or cyclosporin capsules. B007 is given by subcutaneous injection on days 1 and 15, while cyclosporin capsules are taken orally at a dose of 3.5 mg per kg of body weight per day. The study will observe participants over about two years to assess remission rates and monitor safety. During the trial, participants will undergo laboratory tests and assessments to track overall, complete, and partial remission rates. Researchers will also monitor any treatment-emergent adverse events or serious side effects. Participants must meet specific kidney function criteria and will be followed closely throughout the study period until its completion in late 2026.

Age: 18Years - 80YearsAll GendersPhase 2Phase 3
21 locations
E

Actively Recruiting

Researchers are evaluating whether calderasib combined with subcutaneous pembrolizumab can better treat non-small cell lung cancer NSCLC with the KRAS G12C mutation. The study compares this combination to pembrolizumab with chemotherapy to see if it helps patients live longer without their cancer growing or spreading. This is a phase 3 clinical trial assessing treatment effectiveness and safety in participants with advanced or metastatic nonsquamous NSCLC. Participants will be randomly assigned to one of two groups. One group receives pembrolizumab plus berahyaluronidase alfa as a subcutaneous injection every 6 weeks for up to 18 cycles about 2 years, along with calderasib tablets until treatment discontinuation. The other group receives pembrolizumab plus berahyaluronidase alfa with chemotherapy drugs pemetrexed and either carboplatin or cisplatin given intravenously on specified days in the first cycles, also until discontinuation criteria are met. During the study, participants will have regular assessments including tumor scans and health questionnaires to monitor progression free survival, overall survival, response rates, and quality of life. Adverse events and treatment tolerability will also be tracked up to approximately 81 months. The study aims to provide detailed information on the impact of these treatments on cancer progression and patient well-being over time.

Age: 18Years +All GendersPhase 3
221 locations
E

Actively Recruiting

Researchers are investigating new treatment options for people with locally advanced or metastatic colorectal cancer mCRC that cannot be removed by surgery and has a specific gene mutation called KRAS G12C. The study aims to evaluate the safety and tolerance of combining calderasib, cetuximab, and mFOLFOX6 chemotherapy compared to the standard treatment of mFOLFOX6 with or without bevacizumab. This research is a phase 3 clinical trial focused on improving outcomes for this specific patient group. Participants will be assigned to one of two groups. One group receives calderasib tablets orally, cetuximab every two weeks, and mFOLFOX6 chemotherapy including oxaliplatin, leucovorin or levofolinate calcium, and 5-fluorouracil every two weeks. The other group receives mFOLFOX6 chemotherapy with or without bevacizumab or a bevacizumab biosimilar, also administered every two weeks. Treatment continues until doctors decide to stop based on specific criteria. During the study, participants will be closely monitored for side effects and treatment tolerability, with evaluations lasting up to about 44 months in the first part and up to 5 years in the second part. Researchers will collect data on progression-free survival, response rates, overall survival, and quality of life using various questionnaires. Safety assessments and tracking of any adverse events will be conducted regularly throughout the study.

Age: 18Years +All GendersPhase 3
245 locations

1-10 of 583

1